Durable responses after CD19-targeted CAR-T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failureJ. Gauthier,A.V. Hirayama,K.A. Hay, J. Lymp, D. Li, A. Sheih, J. Purushe, B.S. Pender,R.M. Hawkins, A. Vakil, T. Phi,R.N. Steinmetz,S.R. Riddell,D.G. Maloney,C.J. TurtleHematological Oncology(2019)引用 1|浏览6暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要